openPR Logo
Press release

Approaches Toward An HIV Cure: HIV Persistence, Reservoirs & Cure Workshop Takes the Lead and Moves to Miami in 2013

12-30-2011 07:33 AM CET | Health & Medicine

Press release from: CHITS

There are several approaches to finding an HIV cure currently being explored, and all of them have had varying degrees of success. The goal in the HIV research community at this point is to find a "functional cure" for HIV—that is, reducing the viral load in the body to a point where the body's own immune system can keep it in check, without the use of antiretroviral therapy (ART).

Toulon, Var, France, December 29, 2011 -- There are several approaches to finding an HIV cure currently being explored, and all of them have had varying degrees of success. The goal in the HIV research community at this point is to find a "functional cure" for HIV—that is, reducing the viral load in the body to a point where the body's own immune system can keep it in check, without the use of antiretroviral therapy (ART).

While ART is very effective at reducing the viral load in the blood, it is virtually ineffective against dormant HIV virus hiding within infected cells called "reservoirs." These reservoirs are the source of the remaining virus within the body, and become active once it recognizes that ART has stopped.

In 2003 we launched the first edition of the "International Workshop on HIV Persistence, Reservoirs & Eradication Strategies" in Saint Martin, West Indies. This workshop was mainly focused on the nature of the HIV reservoir and mechanisms of maintenance.
Over the years, the workshop became THE reference meeting in the field, attracting more and more scientists from all over the world.
The 5th edition, held in Sint Maarten (Dutch side of the island) in December 2011 was a blast as it attracted more than 215 researchers, many of whom from the National Institutes of Health (NIH) of America.

This last edition still focused on the pathophysiology of HIV reservoirs but contained several sessions on practical therapeutic intervention to alter these reservoirs, a clear evolution over the years.

Different approaches currently attempt to fool the HIV hiding within the reservoirs that ART has stopped. Certain types of drugs inhibit the infected cell's ability to shut itself off, keeping the HIV hiding within from going dormant. Another strategy involves using vaccination before people are exposed to the disease; this strategy is still far off, as a "functional cure" will probably be easier to find at this point.

If that doesn't work, the cells can always be genetically altered. Such a procedure has inherent risk, but the results could be astonishing. The Berlin patient—an HIV-infected man who lives HIV-free today after a bone marrow transplant with genetically altered cells—gave this area of HIV cure research a much needed shot in the arm. Research into genetic modification of cells ramped up in earnest, and two general approaches are often discussed—zinc finger nucleases and cell modification.

The key to genetic modification is the CCR5 receptor—the primary avenue in cells that HIV uses to infect. By inhibiting the cell's CCR5 receptor, it makes that cell, and the body's immune system in general, resistant to contracting HIV. Less than 2% of all people have this genetic anomaly naturally, but a less invasive surgery involving zinc finger nucleases attempts to do what a riskier stem cell transplant does. The idea is that drawing a patient's own healthy cells out of the body, treating them with these zinc finger nucleases, and re-inserting them back into the body will eventually "train" the body over time to become resistant to HIV, suppressing the virus on its own after an ART boost to start with.

These are some of the biggest advances in HIV cure research so far, and show that progress toward a cure continues. As long as the funding holds up and remains in place, a cure can't be that much farther away.

In 2013, the "International Workshop on HIV Persistence, Reservoirs & Eradication Strategies" will move for the first time to Miami, Fl, December 3-6. That means that we have 2 years to make more progress in the field and move towards more clinical trials testing an HIV cure.

Contact:
Alain Lafeuillade
CHITS
1208 avenue Colonel Picot
83056 Toulon, France
33-4-94616340
lafeuillade@orange.fr
http://www.hiv-workshop.com

The HIV Persistence Workshop is the Reference Workshop since 2003 on HIV Reservoirs, HIV Eradication and Cure.

CHITS
1208 avenue Colonel Picot
83056 Toulon, France

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Approaches Toward An HIV Cure: HIV Persistence, Reservoirs & Cure Workshop Takes the Lead and Moves to Miami in 2013 here

News-ID: 205619 • Views:

More Releases from CHITS

05-31-2011 | Health & Medicine
CHITS
An International AIDS 2012 Conference Based on Excellence
Toulon, France, May 30, 2011 -- The ISHEID AIDS 2012 conference announced that the focus will be on topics such as understanding the survival and maintenance mechanisms of HIV, attempting to develop a permanent cure. The worldwide socio-economic and human rights aspects, which can influence the fight against HIV. The discussions will include the usual talks about precautions necessary to prevent transmission of HIV and providing better access to health

More Releases for HIV

HIV Drugs Market - Defeating HIV Together: Advancing Treatment Options for a Bri …
Newark, New Castle, USA: The "HIV Drugs Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors HIV Drugs Market: https://www.growthplusreports.com/report/hiv-drugs-market/7792 This latest report researches the industry structure, sales, revenue,
HIV-Associated Lipodystrophy Treatment Market - Increasing prevalence of HIV is …
HIV-associated lipodystrophy also known as lipodystrophy is a syndrome that occurs in HIV-infected patients. It is characterized by loss of subcutaneous fat from face, buttocks, arms and legs. Although the exact cause of HIV-associated lipodystrophy is not fully elucidated, some research evidence reported that it occurs in HIV-infected patients who are under antiretroviral medications. According to an article published in National Center for Biotechnology Information (NCBI) in 2014, prevalence of
Global HIV Drugs Market | Global HIV Drugs Industry | Global HIV Drugs Market Re …
Human immunodeficiency Virus (HIV) could be a chronic and severe sickness which might be transferred from one person to a different through blood-to-blood and sexual contact. it's a deadly disease that attacks immune cells called CD-4 cells, creating body vulnerable to infections and alternative diseases. Over the years, the rising prevalence of HIV sickness worldwide has completely influenced the demand for HIV medicine. HIV medicine facilitate in preventing the multiplication
HIV Therapeutics Market– South Africa's Aspen launches three-in-one HIV drug
Recent Developments Aspen Pharma care, a South Africa’s drug maker has launched a triple combination of tablet for the treatment of HIV in the country where the HIV virus is the most prevalent. The company's new Emdolten drug is a once a day tablet which is in the form of dolutegravir, an antiretroviral medication that balances the drug’s resistance. The company has launched Aspen Stavudine which was its first generic ARV
HIV Vaccine Market HIV Vaccine Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents Introduction to Human Immunodeficiency Virus (HIV) Vaccines 1.1 Overview 1.2 Antiquity of HIV Vaccine Need for the Development of HIV Vaccine Primer of HIV inside the Body 3.1 Inclusion of HIV Virus into the System 3.2 Interaction of HIV with Host 3.3 Eradication of HIV Virus HIV Vaccine Development Process 4.1 Introduction
Global HIV Vaccine Market & HIV Vaccine Clinical Trial Outlook 2022
Worldwide, around the 35 Million of the people are currently infected with the HIV and about 30 Million of the people died because of the AIDS infection. There is no human example of clearing an HIV infection naturally. HIV virus makes copies of it very quickly, many types of HIV exist and new types of virus are continue to rise. Many scientists are still trying to understand the specific ways